biostudies-literatureUnknown42(9)Marotte HPfizerCHU Saint-Étienne<h4>Introduction</h4>ReFLECT was a French multicenter, observational cohort study evaluating the effectiveness and safety of CT-P13, an infliximab (IFX) biosimilar, in a real-world setting. Here, we describe the results for patients with rheumatic disease.<h4>Methods</h4>Eligible patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA) were recruited and received intravenous CT-P13 induction and/or maintenance therapy. Patients were either naive to IFX (IFX-naive) or had been previously treated with IFX originator or another IFX biosimilar (IFX-switched). CT-P13 persistence (primary objective) was measured as a time-dependent variable during a 2-year follow-up period. Safety was also assessed.<h4>Results</h4>The patient population comprised 142 patAdvances in therapy4659-4680https://www.ebi.ac.uk/biostudies/studies/S-EPMC12394253biostudies-literatureReal-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT).PMC12394253Kessouri MCantagrel ACoury FBrault YFautrel BMarotte HSchaeverbeke TAssing MfalseReal-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT).<h4>Introduction</h4>ReFLECT was a French multicenter, observational cohort study evaluating the effectiveness and safety of CT-P13, an infliximab (IFX) biosimilar, in a real-world setting. Here, we describe the results for patients with rheumatic disease.<h4>Methods</h4>Eligible patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA) were recruited and received intravenous CT-P13 induction and/or maintenance therapy. Patients were either naive to IFX (IFX-naive) or had been previously treated with IFX originator or another IFX biosimilar (IFX-switched). CT-P13 persistence (primary objective) was measured as a time-dependent variable during a 2-year follow-up period. Safety was also assessed.<h4>Results</h4>The patient population comprised 142 pat2025-01-01T00:00:00Z2025 Sep2026-05-28T07:14:22.415Z2026-04-08T02:24:43.691ZS-EPMC123942534072006110.1007/s12325-025-03304-6